Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: John Zwiener who wrote (14569)	2/11/1998 2:44:00 AM
From: Henry Niman	Respond to of 32384

John, There have been a few reports on carcinomas, but I don't think that mono therapy will produce as dramatic effect. Awhile ago Targretin was used to stabilize lung cancer patients. Tumor size was not affected, but the disease did stabilize. Other reports indicate that PSA levels have dropped in some prostate patients (who may have been on LGD1550). LGND has indicated that ovarian and prostate results will be released soon. I'm guessing that the result is positive although I don't know if its tumor shrinkage, stabilization, or marker reduction. Bernie also indicated that Robinson was fairly excited about the initial breast cancer data. These (and probably all carcinomas mentioned above)results were from advanced patients, so the excitement may be more over disease stabilization, than reduction in tumor size. Of course LGND is now moving into combination therapy and several in vitro models have shown additive effects with rexinoids and SERMs as well as Vitamin D derivatives.